Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism

Blood Neoplasia(2025)10.1016/j.bneo.2025.100130Source: DataRank Database

GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism is a research paper published in Blood Neoplasia (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time.

N/A

0.104DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 0.37)OA: goldTopics (17)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.104

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (11)

Josefine Krüger ORCID,Guifen Liu ORCID,Huihui Ma ORCID,Michael Sang Hughes ORCID,Rajshekhar Chakraborty ORCID

Live enrichment

PubMed:40792016 PMC:PMC12335957 OpenAlex:https://openalex.org/W4411448744

Cancer Research Institute

Grant: S10OD020056

Cancer Research Institute

Grant: CRI4395

Cancer Research Institute

Grant: S10RR027050

Cancer Research Institute

Grant: 6659-23

NIH

Grant: R01CA252756

Leukemia & Lymphoma Society

Grant: 6686-24

National Institutes of Health

Grant: 1S10RR027050-01A1

Becton Dickinson LSR II Analytical Flow Cytometer

National Institutes of Health

Grant: 1S10OD020056-01

BD Biosciences Influx

National Institutes of Health

Grant: 1R01CA252756-01A1

Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma

Fondation Sanofi Espoir

Sanofi

Paula and Rodger Riney Foundation

International Myeloma Society

FWCI

0.37

Citation Percentile

0.6%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.bneo.2025.100130

publisherhttps://doi.org/10.1016/j.bneo.2025.100130

publisherhttps://api.elsevier.com/content/article/PII:S2950328025000652?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2950328025000652?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40792016

Fields of Study

Protein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways03 medical and health sciences0302 clinical medicine

Keywords

Mechanism (biology)Multiple myelomaDegradation (telecommunications)ChemistryCancer researchBiologyImmunologyComputer sciencePhysicsBasic Mechanisms of NeoplasiaDiseases of the blood and blood-forming organsRC633-647.5

Sustainable Development Goals

SDG 0: Zero hunger